Treadmill Cardiovascular Safety Study of Erenumab (AMG 334)
Launched by AMGEN · Oct 13, 2015
Trial Information
Current as of May 10, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- • Inclusion Criteria
- • History of chronic stable angina or at least 3 months prior to screening, with at least 1 angina episode per month
- • Ischemic heart disease documented by myocardial infarction, coronary angiography or a revascularization procedure
- • Receiving stable doses of cardiac medication
- • Completes 2 exercise treadmill tests during screening meeting protocol requirements
- Exclusion Criteria:
- • Participating in another investigational study
- • Current or prior malignancy within 5 years of randomization
- • Known sensitivity to any components of the investigational product
- • Not able to complete all protocol required study visits
- • Having the following within 3 months prior to or during screening: Unstable angina or acute coronary syndrome, transient Ischemic attack (TIA) or stroke, revascularization procedure, or instability in ST-segment depression between screening exercise treadmill tests, as assessed by the core electrocardiograph (ECG) laboratory
About Amgen
Amgen is a leading global biotechnology company dedicated to discovering, developing, manufacturing, and delivering innovative human therapeutics. With a strong focus on areas such as oncology, cardiovascular disease, and inflammation, Amgen leverages advanced science and technology to address complex medical needs. The company is committed to improving patient outcomes through rigorous clinical trials and robust research initiatives, ensuring the highest standards of safety and efficacy in its products. With a rich pipeline of cutting-edge therapies, Amgen continues to be at the forefront of biopharmaceutical advancements, making a significant impact on healthcare worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Atlanta, Georgia, United States
Chicago, Illinois, United States
Las Vegas, Nevada, United States
Christchurch, , New Zealand
Jackson, Tennessee, United States
Haskovo, , Bulgaria
Riga, , Latvia
Krakow, , Poland
Zabrze, , Poland
Bardejov, , Slovakia
Lucenec, , Slovakia
Presov, , Slovakia
Parow, Western Cape, South Africa
New Braunfels, Texas, United States
Jacksonville, Florida, United States
Chicago, Illinois, United States
Sofia, , Bulgaria
Piestany, , Slovakia
Trencin, , Slovakia
Geneva 14, , Switzerland
Jacksonville, Florida, United States
Zilina, , Slovakia
Grafton, Auckland, , New Zealand
Lodz, , Poland
Praha 4, , Czechia
Chomutov, , Czechia
Miami, Florida, United States
Wichita Falls, Texas, United States
Brandys Nad Labem, , Czechia
Pribram Viii, , Czechia
Brezno, , Slovakia
Svidnik, , Slovakia
Miami, Florida, United States
Timisoara, , Romania
Patients applied
Trial Officials
MD
Study Director
Amgen
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials